» Articles » PMID: 2914343

Development of Coronary Heart Disease in Familial Hypercholesterolemia

Overview
Journal Circulation
Date 1989 Feb 1
PMID 2914343
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

We studied the development of coronary artery disease in 10 homozygous and 692 heterozygous patients with familial hypercholesterolemia. Seventy-five (22%) male heterozygotes and 35 (10%) female heterozygotes were affected by myocardial infarction, which was first noted in men in the 3rd decade of life and in women in the 4th decade of life. Thirty-eight (70%) out of the deceased 54 heterozygous patients died of coronary heart disease. The mean age at death was significantly less in male heterozygotes (54 years) than in female heterozygotes (69 years). Five homozygous and 105 male and 56 female heterozygous patients received coronary angiographic evaluation. The regression equations between age (X) and coronary stenosis index (Y) obtained by assigning score (0 to 5) to each of 15 coronary artery segments were Y = 1.57X - 20.43 (r = 0.956, p less than 0.05) in the homozygotes, Y = 0.52X - 9.11 (r = 0.438, p less than 0.001) in the male heterozygotes, and Y = 0.47X - 12.54 (r = 0.343, p less than 0.01) in the female heterozygotes. From these data, we can assume that coronary artery stenosis detectable by angiography will occur after 17 and 25 years of age in male and female heterozygotes, respectively, and the treatment of heterozygotes with lipid-lowering drugs can be delayed until late adolescence.

Citing Articles

Synergistic effects of mutation and glycosylation on disease progression.

Suzuki S, Itoh M Front Mol Biosci. 2025; 12:1550815.

PMID: 39967653 PMC: 11832388. DOI: 10.3389/fmolb.2025.1550815.


Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment.

Hamasaki M, Sakane N, Kotani K Nutrients. 2024; 16(21).

PMID: 39519519 PMC: 11547339. DOI: 10.3390/nu16213686.


Coronary Artery and Carotid Artery Plaques in Patients With Heterozygous Familial Hypercholesterolemia.

Tada H, Nohara A, Usui S, Sakata K, Hayashi K, Fujino N JACC Adv. 2024; 2(8):100594.

PMID: 38938338 PMC: 11198480. DOI: 10.1016/j.jacadv.2023.100594.


Genetic Counseling and Genetic Testing for Familial Hypercholesterolemia.

Tada H, Kawashiri M, Nohara A, Sekiya T, Watanabe A, Takamura M Genes (Basel). 2024; 15(3).

PMID: 38540356 PMC: 10970256. DOI: 10.3390/genes15030297.


Failure of lipid control by PCSK9 inhibitors in compound heterozygous familial hypercholesterolemia complicated with premature myocardial infarction: A case report.

Zhang Z, Yang R, Zhu J, Yang X, Luo H, Wang H Clin Case Rep. 2024; 12(3):e8498.

PMID: 38487640 PMC: 10939999. DOI: 10.1002/ccr3.8498.